The standard business model for Chinese biotech companies has been to develop drugs through early proof-of-concept and then partner with global pharmaceutical firms for ex-China rights.

Data from RevMed presented at the ASCO conference demonstrated a doubling of survival time for patients with pancreatic cancer.

Roderick Wong predicts that within five years, pancreatic cancer survival rates will double again, and a percentage of patients may be cured.

RevMed's treatment increased the median survival for pancreatic cancer from approximately 6-7 months to 13 months.